


**REMARKS**

The present amendment is entered in compliance with 37 C.F.R. § 1.78 and to more succinctly claim the invention disclosed herein. Cancellation or amendment of claims should not be construed as a waiver, and applicants reserve the right to pursue claims to subject matter of claims cancelled or amended herein in future continuing applications. No new matter has been added.

Respectfully submitted,



Giulio A. DeConti, Jr., Esq.  
Registration No. 31,503  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

Dated: 07 January 2002

**Appendix A: marked up versions of amendments showing the changes made**

Related Applications

This application is a national phase application pursuant to 35 U.S.C. § 371 *et seq.* based on international application number PCT/GB00/02623, filed July 7, 2000, which claims priority to GB 9916214.1 and US 60/142,907 both filed on July 9, 1999, and GB 9916315.6 and US 60/142,953 both filed on July 12, 1999.

**Appendix B: marked up version of the claims showing the changes made**

24. (Amended) Process according to claim 22 [or claim 23] in which the cells are cultured in the presence of the inhibitor.

27. (Amended) Process according to [any one of] claim[s] 22 [to 24] wherein the inhibitor is

(i) 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid;

[FIGURE]

(ii) DL-2-amino-5-phosphovaleric acid;

[FIGURE]

(iii) 1,2,3,4-tetrahydroisoquinoline;

[FIGURE]

(iv) cyclohexylsulfamic acid;

[FIGURE]

(v) O-phospho-L-serine;

[FIGURE]

(vi) hexafluoroglutaric acid;

[FIGURE]

(vii) 8-methoxyquinoline-5-sulfonic acid;

[FIGURE]

(viii) 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine;

[FIGURE]

(ix) 3-amino-2-hydroxy-1-propanesulfonic acid;

[FIGURE]

or

(x) 3-dimethylamino-1-propanesulfonic acid

[FIGURE];

or a salt thereof.

32. (Amended) A culture medium or a culture medium pre-mix which comprises an inhibitor or compound as defined in [any one of] claim[s] [2, 4, 22 or] 27.

35. (Amended) *Ex vivo* cells prepared by a process according to [any one of] claim[s] 22 [to 31].

36. (Amended) *Ex vivo* cells according to claim 35 wherein said cells are in a preparation that comprises an inhibitor or compound [as defined in any one of claims 2, 4, 27 or 32] selected from (i) 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; (ii) DL-2-amino-5-phosphovaleric acid; (iii) 1,2,3,4-tetrahydroisoquinoline; (iv) cyclohexylsulfamic acid; (v) O-phospho-L-serine; (vi) hexafluoroglutaric acid; (vii) 8-methoxyquinoline-5-sulfonic acid; (viii) 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-

tetrahydropyridine; (ix) 3-amino-2-hydroxy-1-propanesulfonic acid; or (x) 3-dimethylamino-1-propanesulfonic acid; or a salt thereof.

41. (Amended) A pharmaceutical composition comprising a cell according to claim 35 [, 36 or 37] and a pharmaceutically acceptable carrier or diluent.

43. (Amended) A vessel for containing a culture of cells, which vessel is coated with an inhibitor or compound as defined in [any one of] claim[s] 2 [4, 22 or 27].

44. (Amended) A kit for culturing cells comprising a culture medium or culture medium pre-mix as defined in claim 32 [or a vessel as defined in claim 43].

46. (Amended) Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22 [or 23], comprising contacting a candidate substance with a mammalian cell and determining whether the candidate substance inhibits the formation of fibrils or causes the breakdown of fibrils, (i) the inhibition of formation of fibrils or (ii) the breakdown of fibrils, indication that the substance is an inhibitor that can be used in said process.

47. (Amended) Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22 [or 23], comprising contacting a candidate substance with a protein capable of forming fibrils, or with a fibril, and determining whether the substance inhibits the formation of the protein into a fibril, or whether the substance causes the breakdown of the fibril, (i) inhibition of fibril formation or, (ii) the breakdown of fibrils, indicating that the substance can be used in said process.